Background: The etiology of intradialytic hemodynamic instability is multifactorial. Of the various factors involved, a rise in core temperature seems to be crucial. In this respect, the bioincompatibility of hemodialysis (HD) treatment might play an important role. The application of cool dialysate reduces the number of periods of intradialytic hypotension (IDH) considerably. In rats, roller pump perfusion caused hypotension by shear stress induced platelet aggregation and subsequent serotonin release. During clinical HD, citrate anticoagulation abolished platelet activation almost completely. Hence, citrate anticoagulation might reduce IDH, whereas the beneficial effect of cool dialysate might be partly explained by reduced platelet activation. Methods: In the present study, blood pressure, IDH episodes, platelet activation, platelet aggregation, and serotonin release were studied crossover in 10 patients during HD with dalteparin anticoagulation at normal and low dialysate temperatures and during HD with citrate. Results: Citrate strongly reduced platelet activation, but did not improve IDH. The blood pressure was best preserved during cool-temperature HD, despite manifest platelet activation. Platelet activation was not accompanied by a rise in the plasma serotonin concentration. Conclusions: Three major conclusions can be drawn: (1) it is unlikely that platelet activation and subsequent serotonin release underlie IDH in the clinical situation; (2) the protective effects of cool dialysate on IDH appear to be independent of HD-induced platelet activation, and (3) extrapolating results from rat experiments to the human situation requires uppermost prudence.

1.
Daugirdas JT: Pathophysiology of dialysis hypotension: an update. Am J Kidney Dis 2001;38(4 Suppl 4):S11–S17.
2.
Jassal SV, Douglas JF, Stout RW: Prevalence of central autonomic neuropathy in elderly dialysis patients. Nephrol Dial Transplant 1998;13:1702–1708.
3.
Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004;66:1212–1220.
4.
Sherman RA: Modifying the dialysis prescription to reduce intradialytic hypotension. Am J Kidney Dis 2001;38(4 Suppl 4):S18–S25.
5.
Kooman JP, Moret K, van der Sande FM, Gerlag PG, van den Wall Bake AW, Leunissen KM: Preventing dialysis hypotension: a comparison of usual protective maneuvers. Kidney Int 2001;60:802–803.
6.
van der Sande FM, Kooman JP, Burema JH, Hameleers P, Kerkhofs AM, Barendregt JM, Leunissen KM: Effect of dialysate temperature on energy balance during hemodialysis: quantification of extracorporeal energy transfer. Am J Kidney Dis 1999;33:1115–1121.
7.
Passlick-Deetjen J, Bedenbender-Stoll E: Why thermosensing? A primer on thermoregulation. Nephrol Dial Transplant 2005;20:1784–1789.
8.
Peer G, Itzhakov E, Wollman Y, Chernihovsky T, Grosskopf I, Segev D, Silverberg D, Blum M, Schwartz D, Iaina A: Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant 2001;16:1436–1441.
9.
Beerenhout CH, Noris M, Kooman JP, Porrati F, Binda E, Morigi M, Bekers O, van der Sande FM, Todeschini M, Macconi D, Leunissen KM, Remuzzi G: Nitric oxide synthetic capacity in relation to dialysate temperature. Blood Purif 2004;22:203–209.
10.
Grooteman MP, Nubé MJ: Hemodialysis-related bioincompatibility: fundamental aspects and clinical relevance. Neth J Med 1998;52:169–178.
11.
Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nubé MJ: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006;21:153–159.
12.
Borgdorff P, Fekkes D, Tangelder GJ: Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002;106:2588–2593.
13.
Wolberg AS, Meng ZH, Monroe DM, Hoffman M: A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004;56:1221–1228.
14.
Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ: Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997;12:1387–1393.
15.
Janssen MJ, Huijgens PC, Bouman AA, Oe PL, Donker AJ, van der Meulen J: Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228–1233.
16.
Santoro A, Mancini E, Basile C, Amoroso L, Di Giulio S, Usberti M, Colasanti G, Verzetti G, Rocco A, Imbasciati E, Panzetta G, Bolzani R, Grandi F, Polacchini M: Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney Int 2002;62:1034–1045.
17.
Grooteman MP, van Tellingen A, van Houte AJ, Bos JC, Schoorl M, van Limbeek J, Nubé MJ: Hemodialysis-induced degranulation of polymorphonuclear cells: no correlation between membrane markers and degranulation products. Nephron 2000;85:267–274.
18.
Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl WH: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996;7:234–241.
19.
Zoltowski R, Pawlak R, Matys T, Pietraszek M, Buczko W: Propranolol modifies platelet serotonergic mechanisms in rats. J Physiol Pharmacol 2002;53:265–274.
20.
Sreedhara R, Itagaki I, Lynn B, Hakim RM: Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 1995;25:555–563.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.